当市场被短期涨跌裹挟，当追涨杀跌的声音淹没理性，总有一群人选择站在时间的这一侧。不追逐转瞬即逝的热点，不沉迷短期排 名的狂欢，而是以深入研究为锚，以坚定信念为帆，将目光投向企业成长的本质与经济前行的长期趋势。智通财经推出"绩优长跑 者谈长期主义"专栏，深度访谈这些坚守长期主义的基金经理，拆解他们如何在市场波动中筛选优质资产，如何用耐心对抗焦虑， 如何让时间成为投资路上最坚实的盟友，最终让复利的力量结出丰硕果实。 智通财经11月24日讯（记者 吴雨其）十四年时间，在多数基金经理的职业轨迹中已足以经历多次产品更迭、风格切换与角色变动。但对杜猛 来说，这十四年只有一件事值得坚持：在摩根新兴动力这只基金上，专注做好成长股投资。自2011年开始管理摩根新兴动力基金至今，在行业 内日益减少的长期陪伴者中，杜猛显得格外沉静，也格外笃定。 这份坚持并非出于惯性，而是一种深思熟虑的选择。他始终坚信，真正能穿越周期、兑现长期回报的，是那些能够不断为社会创造价值、具备 核心竞争力的企业，而非一时受追捧的热点标的。"成长股的价值兑现，本身就是一个长期过程。"在他看来，投资最关键的不是踩准节奏，而 是与伟大企业并肩前行，把时间交给价值 ...

Core Viewpoint - The article discusses the current state of the A-share market, highlighting the potential for continued investment opportunities, particularly in sectors like artificial intelligence, engineering machinery, chemicals, power batteries, and non-ferrous metals, despite the market's recovery being seen as a mere correction after previous declines [2][4]. Market Overview - The A-share market has reached 4000 points for the first time in ten years, with many investors achieving good returns this year [1]. - The overall market valuation remains reasonable and potentially undervalued, indicating room for further recovery as policies take effect and the economy rebounds [2]. Investment Focus Areas - The focus remains on transformative opportunities brought by AI, with ongoing tracking for more investment prospects [2]. - Other sectors of interest include engineering machinery, chemicals, power batteries, and non-ferrous metals, with traditional industries also showing potential [2]. Stock Selection Strategy - The strategy emphasizes selecting growth stocks, particularly those with stable earnings growth despite significant past declines, which may yield excess returns as performance materializes [4]. - The investment approach will prioritize sectors benefiting from economic transformation and consumer spending, as disposable income continues to rise [4]. Economic and Market Outlook - The outlook for the fourth quarter suggests that market opportunities may outweigh risks, with a focus on stock selection as the primary strategy [4]. - Factors such as potential interest rate cuts by the Federal Reserve, domestic liquidity easing, and supportive policies are expected to benefit the overall stock market [6]. Sector-Specific Insights - AI is highlighted as a key area for growth, with expectations for significant advancements in commercialization and applications in various fields [6]. - The lithium battery sector is anticipated to see increased demand, particularly from electric vehicles and energy storage, with a positive outlook for the second half of the year [6]. - Non-ferrous metals, particularly copper and gold, are expected to maintain strong demand and profitability due to favorable supply-demand dynamics [8]. Consumer Trends - The article notes a shift in consumer behavior among younger generations, leading to increased spending and the emergence of new consumption patterns, which could benefit specific sectors [17].

Core Insights - The article highlights the significant reforms in China's public fund industry, driven by the China Securities Regulatory Commission's action plan aimed at high-quality development, focusing on fiduciary responsibility and encompassing governance, product innovation, investment operations, and assessment mechanisms [1] - Morgan Asset Management (China) has successfully localized its operations, achieving a non-monetary public fund management scale of 133 billion yuan by Q3 2025, doubling its size in two years and improving its industry ranking by 20 positions, reflecting strong market recognition of its investment management capabilities [1] - The company emphasizes a long-term investment philosophy and has established a robust research-driven culture, which is crucial for generating sustainable alpha for clients [2][6] Company Strategy - Morgan Asset Management (China) has adopted a clear investment research structure, focusing on active management as its core competency, with teams dedicated to growth, balanced growth, and value investments, targeting various risk-return profiles [3] - The firm has identified key investment opportunities in artificial intelligence, leading Chinese manufacturers, and dividend assets, leveraging a dual driver of valuation recovery and earnings growth for structural market opportunities in 2025 [4] - The company has built a systematic talent development mechanism, nurturing fund managers with long-term commitment, evidenced by managers like Du Meng and Li Bo, who have delivered substantial returns over extended periods [4][5] Research and Analysis - Morgan Asset Management promotes a "research compounding" approach, emphasizing the importance of continuous research investment to enhance decision-making quality [6] - The firm has a global research team of 500 analysts, conducting extensive field research and maintaining high-frequency interactions with global teams to integrate local insights with global perspectives [6][7] - A unified research language and framework have been established to facilitate efficient resource sharing and collaboration across regions, enhancing the overall research quality [7] ETF Business Development - Morgan Asset Management has differentiated its ETF offerings by combining active management advantages, becoming the second-largest active ETF issuer globally and leading in net inflows since 2025 [8] - The company has launched 11 ETFs in China, focusing on investor experience and innovative features like quarterly mandatory dividends, catering to various investment strategies [8] - The firm continues to enhance its ETF business by providing localized market insights and strategies through reports and seminars, aiming to support index investors effectively [9] Future Outlook - The asset management industry is expected to increasingly favor long-termism, professional capabilities, and ecosystem collaboration, with Morgan Asset Management committed to refining its practices in investment management, product innovation, and client service [10]

以摩根新兴动力基金为例，该基金成立已满14年，截至9月30日，Wind数据显示，至今年化收益率超过 16%。该基金由业内资深老将杜猛管理，其投资布局兼具前瞻性与持续性，曾较早捕捉电动车产业链投 资机会，近年来又精准布局人工智能等科技产业链，成功把握科技企业价值重估的历史性机会。 谈及后市，杜猛表示，节后市场将迎来三季报业绩与"十五五"产业政策的双重验证，预计市场风格将继 续在科技成长与景气复苏之间动态平衡，在中期向好趋势中寻找结构性机会。中期维度，市场向上逻辑 未改，后续四中全会、经济工作会议值得期待；美元降息周期确认，全球流动性利于新兴市场，市场趋 势向上或仍具确定性。未来关注重点将围绕产业趋势明确、景气度独立及政策支持的方向。 随着2025年三季度行情结束，公募基金最新主动权益投资业绩榜单随之揭晓。国泰海通证券日前发布的 基金业绩排行榜显示，主动股票型与偏股混合型基金今年以来平均收益分别达35.5%和32.4%，整体表 现优于股票ETF31%。 在短期业绩分化的市场环境中，真正历经时间检验的"双十基金"（基金成立满十年，且成立以来年化收 益率超过10%），正以其穿越牛熊的出色表现，成为长期投资者的关注焦点 ...

Core Viewpoint - The article emphasizes the importance of active management and deep research in asset management, highlighting Morgan Asset Management's commitment to these principles over the past two decades, which has led to sustained performance and investor trust [2][3]. Group 1: Active Management and Investment Culture - Morgan Asset Management has built a strong investment culture and a stable research team, focusing on long-term value rather than short-term gains, which has resulted in consistent performance [2][3]. - The average tenure of stock fund managers at Morgan Asset Management is approximately 20 years, with many research analysts having over 15 years of experience, contributing to unique market insights through extensive company research [3][4]. Group 2: Long-Term Performance - As of August 2025, Morgan Asset Management's active equity investment team has achieved an annualized return of 13.03% over the past 20 years, ranking in the top 10 of the industry [5][6]. - The "Double Ten" funds, which have been established for over 10 years and achieved annualized returns exceeding 10%, demonstrate strong resilience through various market cycles [6][18]. Group 3: Fund Performance Highlights - The Morgan Emerging Power Fund has an annualized return of 15.75% since its inception in 2011, while the Morgan China Advantage Fund has achieved a return of 13.51% since 2004 [7][9]. - The Morgan Core Growth Fund and Morgan Technology Frontier Fund have also shown significant returns, with annualized rates of 11.61% and 10.40%, respectively, showcasing the effectiveness of their investment strategies [11][12]. Group 4: Team Development and Global Perspective - Approximately 70% of Morgan Asset Management's equity fund managers are internally promoted, ensuring a cohesive team culture and deep market understanding [14]. - The firm leverages its global platform to access extensive research resources, integrating global insights with local market knowledge to enhance investment decision-making [14][16].

Group 1 - The core viewpoint of the article emphasizes the transition of the public fund industry from a "star model" to a "platform model," focusing on building a "platform-based, integrated, multi-strategy" investment research system [1] - Experienced fund managers with over ten years of management experience are showcasing unique value during this transition, as they have navigated multiple market cycles [1][2] - As of August 31, 2025, there are fewer than 100 fund managers in the public fund industry who have continuously managed the same active equity fund for over ten years, representing only about 5% of equity and mixed product fund managers [1][2] Group 2 - Fund managers with over 14 years of experience have demonstrated impressive performance, with annualized returns exceeding 10% for their representative funds [2] - Notable fund managers include Du Meng from Morgan Asset Management, with an annualized return of 15.7%, and others like Zhu Shaoxing and Li Wei, with returns of 15.4% and 14.8%, respectively [2] - The annualized return of the Shanghai Composite Index over the past 14 years is only 2%, indicating that experienced fund managers can generate substantial performance through long-term investment [2] Group 3 - Active investment has seen a significant performance rebound, with 30% of active stock and mixed funds achieving returns over 50% in the past year [3] - Fund managers with over ten years of experience have shown more stable performance, with Du Meng's managed funds yielding returns between 83% and 96% in the past year [3] Group 4 - Historical data indicates that longer holding periods lead to better investor returns, with a 93.2% positive return rate for holding equity funds for five years [4] Group 5 - The article highlights the importance of a supportive platform and culture for fund managers, with companies that have a deep understanding of equity investment fostering long-term management [8] - Morgan Asset Management has maintained a "long-distance" investment culture, with 80% of its global long-term funds outperforming the industry median over the past decade [8][9] Group 6 - The article concludes that the public fund industry is likely to see more fund managers who adhere to long-termism and leverage team intelligence and systematic methods, which is essential for high-quality development in the industry [9]

Group 1 - The core viewpoint highlights the strong performance of the innovative drug ETF (560900), which saw a more than 2% increase in intraday trading, with significant trading volume and a notable rise in the underlying index [1] - The innovative drug ETF (560900) has shown impressive growth, with a weekly increase leading among comparable funds, and a substantial rise in both scale and shares over the past three months and six months [1] - WuXi AppTec's half-year performance forecast indicates a revenue of approximately 20.8 billion yuan, a year-on-year growth of about 20.64%, and a net profit attributable to shareholders of around 8.6 billion yuan, reflecting a significant year-on-year increase of approximately 101.92% [1] Group 2 - The trend of Chinese innovative drugs going global is accelerating, with the total value of License-out transactions expected to exceed $43 billion in 2024, accounting for nearly 20% of the global market [2] - The current overseas expansion models include "building ships" (self-declaration for overseas listing) and "borrowing ships" (outsourcing or establishing NewCo), with successful examples like BeiGene's Zebrutinib and Legend Biotech's Cilta-cel [2] - The total value of outbound licensing transactions reached $51.9 billion in 2024, with $48.4 billion disclosed in the first half of 2025, indicating a robust growth trajectory for Chinese innovative drugs [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to assist investors in seizing investment opportunities in quality technology companies amid a new wave of technological advancements driven by AI [2] - Various actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund, which aims to capture opportunities in new industries, and the Morgan Smart Connectivity Fund, which targets AI-related sectors [3] - Passive investment options include the Morgan Hang Seng Technology ETF and the Morgan China Innovation Drug Industry ETF, providing investors with easy access to technology and innovative drug sectors [3]

Core Viewpoint - The article discusses the evolving landscape of the Chinese equity market, highlighting a shift in global perception of Chinese assets and the potential for A-shares to catch up with the performance of Hong Kong stocks in the coming months to a year [3]. Group 1: Market Performance - Recent months have shown a recovery in the Chinese market, with A-shares and Hong Kong stocks rebounding quickly after initial shocks from tariff disputes [3]. - The Hang Seng Index has increased by 27.64% from September 24, 2024, to May 31, 2025, while the CSI 300 Index has risen by 19.53% during the same period, indicating a stronger performance in Hong Kong stocks compared to A-shares [3]. Group 2: Investment Focus Areas - Four key sectors are highlighted for future investment: AI, innovative pharmaceuticals, consumer goods, and power batteries [4][5]. - AI is seen as a core direction for global technological development, with significant investment opportunities in computing power and related hardware [4]. - The innovative pharmaceutical sector is expected to grow, driven by advancements in research and development within Chinese companies [7]. - The consumer sector is viewed as having no clear distinction between "new" and "old" consumption, with opportunities arising from cultural exports as China continues to grow as a super economy [4]. - The power battery sector remains promising due to its vast market potential across various applications, including energy storage and robotics [5]. Group 3: Healthcare Sector Insights - The innovative pharmaceutical market is anticipated to be a long-term trend, with China's pharmaceutical capabilities aligning with global standards [7]. - Investment opportunities are focused on companies in pharmaceuticals, medical devices, and high-value consumables, with a preference for firms with strong clinical and sales capabilities [7]. Group 4: Consumer Sector Dynamics - The future performance of the consumer sector is closely tied to domestic demand, which is influenced by residents' income expectations [9]. - Recent consumer subsidies in sectors like automotive and home appliances have created opportunities, and sustained policy support could further drive growth [10]. Group 5: Technology Sector Developments - The technology sector, particularly AI, is expected to play a crucial role in overcoming current economic challenges, with AI development projected to continue for decades [12]. - Investment opportunities are identified in smart driving and humanoid robots, with the latter expected to see production growth in specific industries [12]. Group 6: Manufacturing and Resource Insights - The manufacturing sector is poised for growth, with opportunities for Chinese brands to compete globally due to improved product performance and stability [16]. - Resource-related companies are also highlighted, as limited supply supports pricing and profitability [16]. Group 7: Financial Sector Outlook - The banking sector has shown resilience, with improved performance attributed to better-than-expected corporate conditions outside the real estate sector [18]. - As the economic outlook improves, expectations for the banking sector are also anticipated to recover [18]. Group 8: Consumer Goods Sector Analysis - The white liquor industry is undergoing adjustments primarily due to inventory cycles and operational challenges, with potential for recovery as internal adjustments take place [21].

Group 1 - The innovative drug ETF (560900) has seen a 1.14% increase as of July 4, 2025, with an active trading volume of 12.11% [1] - The CSI Innovative Drug Industry Index (931152) rose by 0.95%, with notable increases in constituent stocks such as Zhenjiang Cell (688520) up 19.31% and Rongchang Bio (688331) up 10.54% [1] - Over the past week, the innovative drug ETF (560900) has accumulated a 3.92% increase, reaching a six-month high in its latest scale [1] Group 2 - The National Healthcare Security Administration and the National Health Commission have jointly issued measures to support the high-quality development of innovative drugs, establishing a full-chain policy loop from R&D to payment [2] - The new policy includes the establishment of a commercial health insurance directory for innovative drugs, allowing for confidential pricing mechanisms and special policy treatments [2] - Jianghai Securities noted that the 2025 policy measures will further stimulate R&D efforts and accelerate the market entry of innovative drugs, marking a transition to the 2.0 phase of support policies [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on quality tech companies amid a new wave of technological advancements driven by AI [2] - Various actively managed funds focus on emerging industry trends, AI opportunities, and sectors like the new energy vehicle supply chain and humanoid robotics [3] - Passive investment options include the Morgan Hang Seng Technology ETF and the Morgan CSI Innovative Drug Industry ETF, providing easy access to tech assets and innovative drug companies in China [3]

Group 1 - The core viewpoint highlights the significant growth and performance of the innovative pharmaceutical ETF (560900), which has seen a 1.64% increase and is experiencing active trading with a turnover of 12.59% and a transaction volume of 4.4435 million yuan [1] - The CSI Innovative Pharmaceutical Industry Index (931152) has also shown strong performance, rising by 1.83%, with notable increases in constituent stocks such as Rongchang Bio (688331) up 10.28%, Zai Lab (688266) up 6.28%, and Yifan Pharmaceutical (002019) up 5.77% [1] - As of June 30, the innovative pharmaceutical ETF (560900) has seen a significant increase in shares by 500,000, ranking first among comparable funds [1] Group 2 - According to Guojin Securities, the global competitiveness of innovative drugs is becoming more prominent, with accelerated external licensing and a trend towards profitability in the industry [1] - The number and quality of new drug approvals in China have continued to improve since the beginning of 2025, with an increasing pace of commercialization for innovative drugs and the introduction of internationally leading new drugs into China [1] - The innovative pharmaceutical sector, which has experienced several years of stagnation, is now considered to be in a value trough [1] Group 3 - The rise of AI is driving a new wave of technological advancements, prompting Morgan Asset Management to integrate its "Global Vision Investment Technology" product line to assist investors in strategically positioning themselves in quality tech companies [1] - Morgan's actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund and the Morgan Smart Connectivity Fund, which targets opportunities in artificial intelligence [2] - The passive investment options include the Morgan Hang Seng Technology ETF and the Morgan CSI Innovative Pharmaceutical Industry ETF, providing easy access to Chinese innovative pharmaceutical companies [2]